Search

Your search keyword '"Potenza C"' showing total 411 results
Start Over Author "Potenza C"
411 results on '"Potenza C"'

1. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

Author

Talamonti M, Russo F, Malara G, Hansel K, Papini M, Cattaneo A, Parodi A, Chiricozzi A, Malagoli P, Bardazzi F, Brazzelli V, Dapavo P, Gisondi P, Zane C, Potenza C, Cantoresi F, Fargnoli MC, Trevisini S, Brianti P, Pescitelli L, Gigante G, Bartezaghi M, Caputo L, Aloisi E, and Costanzo A

Subjects
psoriasis, biologics, interleukin-17a, secukinumab, elderly, Dermatology, RL1-803
Abstract

Marina Talamonti,1 Filomena Russo,2 Giovanna Malara,3,4 Katharina Hansel,5 Manuela Papini,6 Angelo Cattaneo,7 Aurora Parodi,8 Andrea Chiricozzi,9,10 Piergiorgio Malagoli,11 Federico Bardazzi,12 Valeria Brazzelli,13 Paolo Dapavo,14 Paolo Gisondi,15 Cristina Zane,16 Concetta Potenza,17 Franca Cantoresi,18 Maria Concetta Fargnoli,19 Sara Trevisini,20 Pina Brianti,21 Leonardo Pescitelli,22 Giovanni Gigante,23 Marta Bartezaghi,23 Luisa Caputo,23 Elisabetta Aloisi,23 Antonio Costanzo24,25 On behalf of the SUPREME Study Group1Dermatology, University of Rome Tor Vergata, Rome, Italy; 2Department of Medical, Surgical and Neurological Science, Dermatology Section, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy; 3Dermatology Unit, Hospital “Bianchi Melacrino Morelli”, Reggio, Calabria, Italy; 4Department of Dermatology, Papardo Hospital, Messina, Italy; 5Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 6Dermatologic Clinic of Terni, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 7U.O. Dermatologia, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 8Di.S.Sal. Section of Dermatology, Ospedale Policlinico San Martino, University of Genova, Genova GE, 16132, Italy; 9UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy; 10Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; 11Psocare Unit, I.R.C.C.S Policlinico San Donato, Milano, Italy; 12Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 13Dermatology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 14Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Torino, Torino, Italy; 15Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy; 16Dermatology Department, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy; 17Dermatology Unit “Daniele Innocenzi”, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome – Polo Pontino, Latina, Italy; 18Dermatology Unit, Department of Medicine, University of Roma, Roma, Italy; 19Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 20Department of Dermatology, University of Trieste, Trieste, Italy; 21Dermatology and Cosmetology Unit - San Raffaele Hospital, Milan, Italy; 22Department of Health Sciences, Dermatology Clinic, University of Firenze, Firenze, Italy; 23Novartis Farma SpA, Origgio, Italy; 24Unit of Dermatology, IRCCS Humanitas Research Hospital, Milano, Italy; 25Department of Biomedical Sciences, Humanitas University, Milano, ItalyCorrespondence: Marina Talamonti, Dermatology-Department of Systems Medicine, University of Rome Tor Vergata, PTV – Policlinico Tor Vergata, V.le Oxford 81, Rome, 00133, Italy, Tel +39 0620902743, Fax +39 0620902742, Email talamonti.marina@gmail.comPurpose: Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17A approved for the treatment of moderate to severe plaque psoriasis in adults and children. We compared the efficacy and safety of secukinumab in patients aged < 65 years (adult patients) versus patients aged ≥ 65 years (elderly patients) in a post-hoc analysis of the SUPREME study.Patients and Methods: Patients with moderate to severe plaque psoriasis received subcutaneous secukinumab 300 mg per week for the first 5 weeks, then 300 mg per month. We compared the following outcomes in patients aged ≥ 65 years vs < 65 years: baseline characteristics; PASI50/75/90/100 response rates (improvements ≥ 50%/75%/90%/100% in Psoriasis Area and Severity Index (PASI) from baseline); changes in Dermatology Life Quality Index (DLQI); Hospital Anxiety and Depression Scale (HAD-A, HAD-D) score changes; treatment-emergent adverse events (TEAEs).Results: Secukinumab was slightly less effective in elderly patients than in adult patients (response rates at week 16: PASI90, 69.4% vs 80.9%, p = 0.4528; PASI100, 44.4% vs 56.7%, p = 0.8973). Elderly and adult patients showed a similar time course of changes in absolute PASI scores. Patients aged ≥ 65 years had a statistically significantly lower improvement in quality of life (mean DLQI reduction) than patients aged < 65 years at week 16 [− 5.4 (± 4.3) vs − 8.8 (± 6.9), p = 0.0065] and at week 24 [− 5.3 (± 4.4) vs − 9.2 (± 7.1), p = 0.0038]. Secukinumab treatment resulted in comparable mean reductions in anxiety and depression scores in both cohorts at 24 weeks [HAD-A, − 1.3 (± 3.3) vs − 2.1 (± 3.8), p = 0.9004; HAD-D, − 1.0 (± 3.3) vs − 1.5 (± 3.1), p = 0.4598]. The frequency of TEAEs in the two cohorts was similar (16.7% vs 14.6%, p = 0.7391).Conclusion: Secukinumab is a valid option for the management of moderate to severe psoriasis in elderly patients.Keywords: psoriasis, biologics, interleukin-17A, secukinumab, elderly

Published
2023

2. Aesthetic Treatments in Cancer Patients

Author

Proietti I, Skroza N, Mambrin A, Marraffa F, Tolino E, Bernardini N, Marchesiello A, Rossi G, Volpe S, and Potenza C

Subjects
aesthetic treatment, cancer patient, fillers, botulinum toxin, laser therapy, Dermatology, RL1-803
Abstract

Ilaria Proietti,1 Nevena Skroza,1 Alessandra Mambrin,1 Federica Marraffa,2 Ersilia Tolino,1 Nicoletta Bernardini,1 Anna Marchesiello,1 Giovanni Rossi,1 Salvatore Volpe,1 Concetta Potenza1 1Dermatology Unit “Daniele Innocenzi”, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy; 2Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, ItalyCorrespondence: Ilaria ProiettiDermatology Unit “Daniele Innocenzi”, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, ItalyEmail ilaria.proietti@uniroma1.itAbstract: Cancer patients are experiencing an increase in overall survival as a consequence of earlier diagnosis and newer effective anticancer therapies. However, cancer survivors often face long-term consequences from their original cancer diagnosis and long-term sequelae of anticancer treatment. Maintaining patients’ quality of life is of paramount importance and this can be accomplished by a multidisciplinary treatment approach, including aesthetic treatments to improve patients’ body image and positively impact their quality of life. In this perspective, we will discuss the importance of aesthetic treatments in cancer patients. In addition, we will summarise the data available regarding the use of several aesthetic treatments such as fillers, botulinum toxin and laser use in cancer patients, their safety, their efficacy, and the specific precautions that need to be implemented in this particular subset of cancer patients.Keywords: aesthetic treatment, cancer patient, fillers, botulinum toxin, laser therapy

Published
2021

3. Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice

Author

Skroza N, Bernardini N, Proietti I, and Potenza C

Subjects
ingenol mebutate, actinic keratosis, field cancerization, real world, photodamage, novel treatment, Therapeutics. Pharmacology, RM1-950
Abstract

Nevena Skroza, Nicoletta Bernardini, Ilaria Proietti, Concetta Potenza Dermatology Unit “Daniele Innocenzi”, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, 04019 Terracina, Italy Abstract: Actinic keratoses (AKs) are epidermal cutaneous neoplasia observed predominantly in middle-aged and older subjects with mainly photo type I and photo type II on sun-exposed surfaces as a result of DNA damage. AKs have historically been characterized as being “precancerous”; however, now it is considered by many authors a carcinoma in situ that can persist or progress to invasive squamous cell carcinoma (SCC) with metastatic potential. Despite the advances in the recognition of typical clinic, dermoscopic and histologic patterns, currently it is not yet possible to predict which AKs will progress to SCC. For this reason, early diagnosis and effective therapy are recommended based on cost/risk/benefit analysis. Current treatment consists of lesion-directed or field-directed therapies or a combination of both. Among the topical field therapies, ingenol mebutate stands out for its therapeutic efficacy, both as directed lesion therapy and as field directed therapy. The aim of this review is to demonstrate the utility of ingenol mebutate in the management of AK in daily clinical practice and to highlight data from real world in order to confirm evidence from pivotal studies. In order to explore clinical data from real world, PubMed searches were performed with the search terms “clinical data ingenol mebutate” and “real world ingenol mebutate”. The hits were examined for relevant articles using defaults criteria. The timeframe for the sample search started from the first publication on this topic in 2008 up to now. A total of 23 articles were found using the keywords specified above. The overview points out a low number of real-life studies on the effectiveness and tolerability of this novel treatment due to short period of clinical experience for its recent approval. Further real-life studies are required in order to better identify the efficacy, safety and adherence of the drug on a larger population. Keywords: ingenol mebutate, actinic keratosis, field cancerization, real world, photodamage, novel treatment

Published
2018

5. Epidemiology, characteristics of disease and unmet needs of patients with generalized pustular psoriasis: a large Italian Delphi consensus

Author

Prignano, F, Atzori, L, Bellinato, F, Damiani, G, Galeone, C, Mariani, P, Potenza, C, Scopinaro, A, Piaserico, S, Fabbrocini, G, Prignano, F, Atzori, L, Bellinato, F, Damiani, G, Galeone, C, Mariani, P, Potenza, C, Scopinaro, A, Piaserico, S, and Fabbrocini, G

Abstract

Introduction: Generalized pustular psoriasis (GPP) is a rare and chronic, debilitating skin condition characterized, in its acute flare phase, by clinically severe and potentially lifethreatening systemic manifestations. Data on GPP are still scanty, particularly in Europe and at a national level. The aim of this study was to provide expert indications on several disease-related and patient-related aspects of GPP, with specific focus to the Italian context. Methods: We conducted an iterative eDelphi study following the recommended criteria for reporting methods and results. After a thorough bibliographic review aimed to identify unknown or controversial issues in GPP, the following areas were investigated through a few specific questions/statements for each area: (1) disease epidemiology; (2) disease characteristics, with specific interest toward GPP flares; (3) diagnosis and diagnostic delay; (4) GPP treatment; (5) GPP patient journey and use of healthcare resources in Italy; (6) unmet needs and quality of life. An Executive Board of 9 principal investigators revised and approved the topics to be examined and overviewed the whole project. A total of 35 experts from different Italian areas, including 34 board-certified Italian dermatologists and 1 representative of patients' associations, took part in the study. Results: A high agreement in responses from Italian experts emerged during two eDelphi iterations on - among several other aspects - GPP prevalence and incidence in Italy, use of European Rare and Severe Psoriasis Expert Network diagnostic criteria, flare frequency and duration, best diagnostic and care pathway, and main unmet needs of Italian patients. On the other hand, a broad spectrum of treatments (of different drug classes) was reported both in the acute and chronic phases of GPP, and no consensus on the issue was thus achieved. Conclusions: Consensus findings from this Delphi study of GPP experts may be useful to fill gaps of knowledge and improve awa

Published
2024

6. PsoBioVax: A multicentric Italian case–control study of the immunological response to anti‐SARS‐CoV‐2 vaccine among psoriatic patients under biological therapy

Author

Sacchelli, L., primary, Filippi, F., additional, Balato, A., additional, Balestri, R., additional, Bellinato, F., additional, Bernardini, N., additional, Bianchi, L., additional, Burlando, M., additional, Campanati, A., additional, Chessa, M. A., additional, Corazza, M., additional, Di Cesare, A., additional, Di Lernia, V., additional, Diotallevi, F., additional, Esposito, M., additional, Fargnoli, M. C., additional, Gisondi, P., additional, Giunta, A., additional, Hansel, K., additional, Magnano, M., additional, Megna, M., additional, Odorici, G., additional, Prignano, F., additional, Potenza, C., additional, Rech, G., additional, Rovesti, M., additional, Ruggiero, A., additional, Satolli, F., additional, Stingeni, L., additional, Gibertoni, D., additional, and Bardazzi, F., additional

Published
2023
Full Text
View/download PDF

7. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., Peris, K., Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., and Peris, K.

Published
2022

8. Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study

Author

Gori, Niccolo', Sernicola, A., Tolino, E., Mariano, M., Galluzzo, M., Moretta, G., Coppola, R., D'Alessio, A., Sansone, Martina, Maffei, V., Paolino, C., Ferrao, C., Cascia, L., Addio, P., Di Nardo, Lucia, Chiricozzi, Andrea, Del Duca, E., Cristaudo, A., Bianchi, L., Pallotta, S., Panasiti, V., Pellacani, G., Potenza, C., Peris, Ketty, Gori N., Sansone M., Di Nardo L., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Gori, Niccolo', Sernicola, A., Tolino, E., Mariano, M., Galluzzo, M., Moretta, G., Coppola, R., D'Alessio, A., Sansone, Martina, Maffei, V., Paolino, C., Ferrao, C., Cascia, L., Addio, P., Di Nardo, Lucia, Chiricozzi, Andrea, Del Duca, E., Cristaudo, A., Bianchi, L., Pallotta, S., Panasiti, V., Pellacani, G., Potenza, C., Peris, Ketty, Gori N., Sansone M., Di Nardo L., Chiricozzi A. (ORCID:0000-0002-6739-0387), and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Objectives: The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe atopic dermatitis (AD), and to investigate the clinical, demographic and predictive factors influencing the patients’ treatment persistence. Material and methods: This study included adult patients affected by moderate-to-severe AD treated with dupilumab for at least 16 weeks who visited 7 dermatologic outpatient clinics in Lazio, Italy, from January 2019 until August 2021. Results: A total of 659 adult patients (345 male [52.3%], mean age: 42.8 years) with an average treatment duration of 23.3 months were enrolled in the study. Overall, 88.6% and 76.1% of patients were still on treatment after 12 and 24 months, respectively. The drug survival rate for discontinuation due to AEs and dupilumab ineffectiveness was 95.0% at 12 months and 90.0% at 24 months. The main reasons for drug discontinuation included inefficacy (29.6%), failed compliance (17.4%), persistent efficacy (20.4%) and adverse events (7.8%). Adult AD onset (≥18 years) and EASI score severity measured at the last follow-up visit were the only factors significantly associated with lower drug survival. Conclusion: This study revealed an increased cumulative probability of dupilumab survival at 2 years, reflected by a sustained effectiveness and a favorable safety profile of the drug.

Published
2023

9. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study

Author

Giofre, C., Fabbrocini, G., Potenza, C., Tiberio, R., Gisondi, P., Marasca, C., Nuzzo, C. M. A., Benincasa, E., Bianchi, L., Dapavo, P., Parodi, A., Atzori, L., Pasquale, R., Peris, Ketty, Amerio, P., Venturini, M., Schiavo, A. L., Romanelli, Margherita, Richetta, A., Cusano, F., Fargnoli, Maria Concetta, Offidani, A., Guarneri, C., Prignano, F., Corazza, M., Bongiorno, M. R., Loconsole, F., Ori, A., Simoni, L., Amici, C., Palma, L. D., Andreis, D., Trevisan, F., Sala, S., Patane, R., Mele, F., Pernaci, A., Ruberti, S., Trogu, M., Pelicelli, S., Rizzoli, S., Peris K. (ORCID:0000-0002-5237-0463), Romanelli M., Fargnoli M. C., Giofre, C., Fabbrocini, G., Potenza, C., Tiberio, R., Gisondi, P., Marasca, C., Nuzzo, C. M. A., Benincasa, E., Bianchi, L., Dapavo, P., Parodi, A., Atzori, L., Pasquale, R., Peris, Ketty, Amerio, P., Venturini, M., Schiavo, A. L., Romanelli, Margherita, Richetta, A., Cusano, F., Fargnoli, Maria Concetta, Offidani, A., Guarneri, C., Prignano, F., Corazza, M., Bongiorno, M. R., Loconsole, F., Ori, A., Simoni, L., Amici, C., Palma, L. D., Andreis, D., Trevisan, F., Sala, S., Patane, R., Mele, F., Pernaci, A., Ruberti, S., Trogu, M., Pelicelli, S., Rizzoli, S., Peris K. (ORCID:0000-0002-5237-0463), Romanelli M., and Fargnoli M. C.

Abstract

Introduction: While several European studies have reported real-world apremilast use, patient-perceived benefits, and treatment satisfaction, local reimbursement criteria for apremilast vary and data from Italy are limited. Methods: The cross-sectional DARWIN study enrolled consecutive patients who had initiated apremilast for plaque psoriasis 6 (± 1) months prior to enrolment at a single visit across 24 Italian dermatological sites. Disease severity was assessed using body surface area (BSA) and Physician Global Assessment (PGA). Patient-reported outcomes assessed 6 (± 1) months after apremilast initiation were Dermatology Life Quality Index (DLQI), Patient Benefit Index (PBI), and 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9). Results: Of 184 patients enrolled between July 2019 and January 2021, 180 were included in the analysis. At apremilast initiation, median (25th–75th percentile) time since psoriasis diagnosis was 8.6 (3.2–22.2) years; median BSA, 10.0% (5.0–16.0); mean (standard seviation, SD) DLQI total score, 13.5 (8.0). Over half (54.9%) of patients with available data reported psoriasis had a very or extremely large effect on their quality of life (QoL); half reported itching (50.6%) and/or special areas involvement (50.0%). Most (73.9%) had comorbidities and were biologic-naïve (81.5%). The most common reasons for initiating apremilast were lack of efficacy of previous treatment (56.7%) and contraindications to other treatments (44.4%). At 6 (± 1) months, most patients were continuing apremilast and/or reported a Global PBI score ≥ 1 (minimum clinical benefit) (86.1% and 90.0%, respectively); approximately half achieved BSA ≤ 3% and/or DLQI total score ≤ 5 (47.1% and 48.5%); 18.8% achieved PGA = 0; mean (SD) TSQM-9 global treatment satisfaction score was 59.0 (24.8). Apremilast was well tolerated; no new safety signals were identified. Conclusions: Patients treated with apremilast for 6 months in Italian clinical practice rep

Published
2023

10. Mycosis fungoides: creation of a prospective, interdisciplinary and multicenter study in central Italy

Author

Ardigo, M., Bianchi, L., Cantisani, C., Cota, C., Di Raimondo, C., Di Stefani, Alessandro, Fargnoli, Maria Concetta, Franceschini, Catia, Pellacani, G., Peris, Ketty, Persechino, S., Plebani, S., Potenza, C., Proietti, I., Quattrini, Laura, Cantonetti, M., Di Stefani A., Fargnoli M. C., Franceschini C., Peris K. (ORCID:0000-0002-5237-0463), Quattrini L., Ardigo, M., Bianchi, L., Cantisani, C., Cota, C., Di Raimondo, C., Di Stefani, Alessandro, Fargnoli, Maria Concetta, Franceschini, Catia, Pellacani, G., Peris, Ketty, Persechino, S., Plebani, S., Potenza, C., Proietti, I., Quattrini, Laura, Cantonetti, M., Di Stefani A., Fargnoli M. C., Franceschini C., Peris K. (ORCID:0000-0002-5237-0463), and Quattrini L.

Abstract

na

Published
2023

11. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author

Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., Piras V., Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., and Piras V.

Abstract

Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.

Published
2021

12. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Author

Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., and Peris, K.

Abstract

Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen ‘cytokine storm’ of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021

13. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Hansel, K., Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli, Mc, Esposito, M, Ferrucci, S, Girolomoni, G, Offidani, A, Patrizi, A, Peris, K, Costanzo, A, Malara, G, Pellacani, G, Romanelli, M, Amerio, P, Cristaudo, A, Flori, Ml, Motolese, A, Betto, P, Patruno, C, Pigatto, P, Sirna, R, Stinco, G, Zalaudek, I, Bianchi, L, Boccaletti, V, Cannavò, Sp, Cusano, F, Lembo, S, Mozzillo, R, Gallo, R, Potenza, C, Rongioletti, F, Tiberio, R, Grieco, T, Micali, G, Persechino, S, Pettinato, M, Pucci, S, Savi, E, Stingeni, L, Romano, A, Argenziano, G, and Dupilumab Italian National Access Program (Dup-INAP, group).

Subjects
Male, Dermatitis, Severity of Illness Index, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Quality of life, Monoclonal, 80 and over, Humanized, Aged, 80 and over, Real-life, Atopic dermatitis, Middle Aged, Atopic dermatiti, Dupilumab, humanities, Treatment Outcome, atopic dermatitis, dupilumab, real-life, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Cohort study, atopic dermatiti, Adult, medicine.medical_specialty, Context (language use), Dermatology, Antibodies, Monoclonal, Humanized, Antibodies, Atopic, Dermatitis, Atopic, 03 medical and health sciences, Young Adult, Internal medicine, Severity of illness, medicine, Humans, Adverse effect, Aged, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, Pruritus, Retrospective cohort study, medicine.disease, Quality of Life, business, Sleep
Abstract

Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.

Published
2021

14. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author

Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., Zangrilli A., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., and Zangrilli A.

Published
2020

15. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study

Author

Caldarola, G., Galluzzo, M., Bernardini, N., Calabrese, L., Grimaldi, M., Moretta, G., Pagnanelli, G., Shumak, R. G., Talamonti, M., Tofani, L., Pallotta, S., Peris, K., Potenza, C., De Simone, C., Campione, E., Caldarola G. (ORCID:0000-0002-8837-9232), Peris K. (ORCID:0000-0002-5237-0463), De Simone C. (ORCID:0000-0002-0898-0045), Caldarola, G., Galluzzo, M., Bernardini, N., Calabrese, L., Grimaldi, M., Moretta, G., Pagnanelli, G., Shumak, R. G., Talamonti, M., Tofani, L., Pallotta, S., Peris, K., Potenza, C., De Simone, C., Campione, E., Caldarola G. (ORCID:0000-0002-8837-9232), Peris K. (ORCID:0000-0002-5237-0463), and De Simone C. (ORCID:0000-0002-0898-0045)

Abstract

New biologic agents targeting interleukin (IL)23/T-helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected by moderate-to-severe psoriasis over a 28-week treatment period. A multicentric retrospective study was conducted in patients who initiated tildrakizumab between February 2020 and March 2021. Psoriasis Area and Severity Index—PASI was measured at baseline and after 4, 16 and 28 weeks. The percentage change in PASI value from baseline to the considered time-points, proportion of patients with absolute PASI <3 at week 28 and the percentages of achieving a PASI75 or PASI90 response were assessed. Data about potential safety issues and adverse events (AEs) were collected. Statistical analysis were performed for establish clinical efficacy and for variables predicting clinical response. Fifty nine patients with psoriasis were included. Overall mean PASI percentage reduction was of 88% from baseline to week 28 and 47 out of 59 patients (79.7%) at week 28 had an absolute PASI <3. PASI75 and PASI90 responses at week 28 were achieved by 48 (81.40%) patients and 38 (64.4.0%) patients, respectively. No substantial associations between gender, body mass index - BMI, PASI at baseline and prior exposition to biological therapies and the efficacy endpoints were retrieved. No serious safety issues or discontinuations related to adverse events were reported. In our real-life study, tildrakizumab showed high efficacy and a favorable safety profile, regardless of patient- and disease-related factors.

Published
2022

16. Adverse skin reactions to personal protective equipment during COVID-19 pandemic in Italian health care workers

Author

Proietti, I., Borrelli, Ivan, Skroza, N., Santoro, Paolo Emilio, Gualano, M. R., Bernardini, N., Mambrin, A., Tolino, E., Marchesiello, A., Marraffa, F., Michelini, S., Rossi, G., Volpe, S., Ricciardi, Walter, Moscato, Umberto, Potenza, C., Borrelli I. (ORCID:0000-0002-6361-8823), Santoro P. E. (ORCID:0000-0002-6052-088X), Ricciardi W. (ORCID:0000-0002-5655-688X), Moscato U. (ORCID:0000-0002-2568-3966), Proietti, I., Borrelli, Ivan, Skroza, N., Santoro, Paolo Emilio, Gualano, M. R., Bernardini, N., Mambrin, A., Tolino, E., Marchesiello, A., Marraffa, F., Michelini, S., Rossi, G., Volpe, S., Ricciardi, Walter, Moscato, Umberto, Potenza, C., Borrelli I. (ORCID:0000-0002-6361-8823), Santoro P. E. (ORCID:0000-0002-6052-088X), Ricciardi W. (ORCID:0000-0002-5655-688X), and Moscato U. (ORCID:0000-0002-2568-3966)

Abstract

To avoid exposure to SARS-COV-2, healthcare professionals must use personal protective equipment (PPE). Their use has been related to a series of adverse effects; the most frequent adverse events were headache, dyspnoea, and pressure injuries. Skin adverse effects are very common, including contact dermatitis, itching, erythema, and acneiform eruptions. The objective of this study is to evaluate the skin problems caused by personal protection equipment (PPE) in health care workers (HCWs) and to individuate eventual risk factors. From May to June 2020 a retrospective observational multi-centric study conducted by an online survey sent by email, involving 10 hospital centers, was performed. We considered as independent variables gender and age, occupational group and sector, time of utilization, type and material of PPE. We tested 3 types of PPE: gloves, bonnet, and mask for different time of utilization (<1, 1–3, 3–6, >6 h). We performed a multiple logistic regression model to correlate them with skin adverse events occurrence. Among all the 1184 participants, 292 workers reported a dermatological pathology: 45 (15.41%) had psoriasis, 54 (18.49%) eczema, 38 (13.01%) acne, 48 (16.44%) seborrheic dermatitis, and 107 (36.64%) other. In our sample previous inflammatory dermatological conditions, female sex, prolonged use of PPE were significant risk factors for developing skin related adverse events considering all the PPE considered. The use of PPE is still mandatory in the hospital setting and skin adverse reactions still represent a global problem. Although data from Europe are limited, our study highlighted the importance of the problem of PPE skin reactions in a large sample of Italian healthcare professionals.

Published
2022

17. The Dermatological Effects and Occupational Impacts of Personal Protective Equipment on a Large Sample of Healthcare Workers During the COVID-19 Pandemic

Author

Santoro, Paolo Emilio, Borrelli, Ivan, Gualano, M. R., Proietti, I., Skroza, N., Rossi, Maria Francesca, Amantea, Carlotta, Daniele, Alessandra, Ricciardi, Walter, Potenza, C., Moscato, Umberto, Santoro P. E. (ORCID:0000-0002-6052-088X), Borrelli I. (ORCID:0000-0002-6361-8823), Rossi M. F., Amantea C., Daniele A., Ricciardi W. (ORCID:0000-0002-5655-688X), Moscato U. (ORCID:0000-0002-2568-3966), Santoro, Paolo Emilio, Borrelli, Ivan, Gualano, M. R., Proietti, I., Skroza, N., Rossi, Maria Francesca, Amantea, Carlotta, Daniele, Alessandra, Ricciardi, Walter, Potenza, C., Moscato, Umberto, Santoro P. E. (ORCID:0000-0002-6052-088X), Borrelli I. (ORCID:0000-0002-6361-8823), Rossi M. F., Amantea C., Daniele A., Ricciardi W. (ORCID:0000-0002-5655-688X), and Moscato U. (ORCID:0000-0002-2568-3966)

Abstract

Introduction: Working during the Sars-CoV-2 pandemic healthcare workers (HCWs) had to wear Personal Protective Equipment (PPEs) for extended periods of time, leading to an increase in dermatological reactions. The study evaluates the prevalence of adverse skin reactions to PPEs among Italian healthcare workers during the COVID-19 pandemic, and aims to determine whether prolonged PPEs usage poses a significant occupational health risk, by measuring the loss of work days and the eligibility of workers that requested health surveillance due to dermatological PPEs reactions. Materials and Methods: An online ad hoc questionnaire was administered to a sample of Italian HCWs. Questions verted on sociodemographic characteristics, PPEs usage, and occupational well-being. Descriptive analyses and logistic regressions were performed to explore possible associations between variables. Results: Two types of PPEs, Gloves and Masks, were tested. The sample included 1,223 interviewed HCWs, 1,184 gave their consent for participation. A total of 90 medical surveillance visits were requested due to PPEs related dermatological issues: in 30 cases were recognized limitations in working duties and in one case the worker was deemed not fit to keep working. Furthermore, 25 workers had a loss of occupational days due to dermatological issues. A statistically significant correlation was observed with being a nurse or midwife (OR = 1.91, IC = 1.38–2.63, p < 0.001), and being female (OR = 2.04, IC = 1.49–2.78, p < 0.001), which acted as risk factors. Discussion: The enhanced protection measures put in place during the COVID-19 pandemic, highlight the importance of occupational dermatology. This study could contribute to assess the issue, aiming to develop better prevention strategies in the workplace in order to improve well-being of HCWs and reduce the impact of dermatological adverse reactions to PPEs.

Published
2022

18. Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis. The LION real-life multicenter prospective observational cohort study

Author

Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., Pigatto, P., Cruciani, G., De Simone, C., Caldarola, G., Grimaldi, M., Anedda, J., Bernardini, N., Marchesiello, A., Franchi, C., Dattola, A., Botti, E., Zedde, P., Cammarata, E., Radi, G., Rosi, E., De Rosa, A., Esposito, M., Marietti, R., Lupi, F., Grazzini, M., Domenico, D. M., Brusasco, M., Gai, F., Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., and on behalf of the LION study group—Italian Participating, Centers

Subjects
Adult, Male, medicine.medical_specialty, Dermatologic Agent, psoriasis, therapy-topical, Betamethasone dipropionate, Dermatology, Betamethasone, NO, chemistry.chemical_compound, Patient satisfaction, Calcitriol, Psoriasis, Internal medicine, Drug Combination, medicine, Humans, Prospective Studies, Prospective cohort study, Calcipotriol, psoriasi, therapy-topical, business.industry, psoriasis, General Medicine, Middle Aged, medicine.disease, Prospective Studie, Drug Combinations, Treatment Outcome, chemistry, Patient Satisfaction, Cohort, Observational study, Dermatologic Agents, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Cohort study, medicine.drug, Human
Abstract

Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. This study assessed patient's satisfaction with Cal/BD foam in a real-life Italian dermatological clinical practice. A multicenter, 4-week observational prospective cohort study enrolled, in 17 Italian dermatology clinics, adult patients with plaque psoriasis on the body and/or scalp. Treatment satisfaction was assessed by 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), preference over previous treatments by Patient Preference Questionnaire (PPQ), and change in disease state by Psoriasis Area Severity Index (PASI). Overall 256 patients were eligible, with a mean (SD) age of 55.6 (15.4) years, 59.4% were males. Psoriasis severity was mild in 52.0% of patients, moderate in 43.3%, and severe in 4.7%. Scalp involvement was present in 36.7% of patients. Previous antipsoriatic treatments had been received by 80.5% of patients. TSQM-9 median (25th-75th percentile) scores were 83.3 (66.7-88.9) for effectiveness, 77.8 (66.7-88.9) for convenience, and 78.6 (64.3-92.9) for global satisfaction. Mean (SD) PASI value decreased from 7.3 (4.8) to 2.1 (2.7) after 4 weeks. More than 90% of patients previously treated for psoriasis evaluated the Cal/BD foam more effective, easier to use and better tolerated compared to previous topical treatments at PPQ. This observational study provides real-life evidence of a high level of satisfaction with effectiveness and convenience of the Cal/BD foam in a cohort of plaque psoriasis patients, with an objective improvement in PASI.

Published
2021

19. Non‐invasive instrumental examinations of cutaneous, adnexal and mucosal manifestations after SARS‐COV‐2 infection in adult and children

Author

Proietti, I., primary, Tolino, E., additional, Mambrin, A., additional, Skroza, N., additional, Bernardini, N., additional, Marchesiello, A., additional, Marraffa, F., additional, Michelini, S., additional, Rossi, G., additional, Volpe, S., additional, Del Giudice, E., additional, Lubrano, R., additional, and Potenza, C., additional

Published
2021
Full Text
View/download PDF

20. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Author

Patruno C., Napolitano M., Argenziano G., Peris K., Ortoncelli M., Girolomoni G., Offidani A., Ferrucci S. M., Amoruso G. F., Rossi M., Stingeni L., Malara G., Grieco T., Foti C., Gattoni M., Loi C., Iannone M., Talamonti M., Stinco G., Rongioletti F., Pigatto P. D., Cristaudo A., Nettis E., Corazza M., Guarneri F., Amerio P., Esposito M., Belloni Fortina A., Potenza C., Fabbrocini G., Angileri L., Bianchelli T., Borghi A., Buligan C., Calabrese G., Calzavara Pinton P., Caroppo F., Chello C., Dal Bello G., Damiani G., Fargnoli M. C., Ferrillo M., Galluzzo M., Gori N., Gualdi G., Hansel K., Macchia L., Mariano M., Nistico S. P., Pertusi G., Piras V., Provenzano E., Ravaioli G. M., Ribero S., Romanelli M., Romita P., Tolino E., Trifiro C., Patruno, C., Napolitano, M., Argenziano, G., Peris, K., Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, M., Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, M. C., Ferrillo, M., Galluzzo, M., Gori, N., Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, E., Ravaioli, G. M., Ribero, S., Romanelli, M., Romita, P., Tolino, E., and Trifiro, C.

Subjects
Adult, medicine.medical_specialty, Adolescent, multicentre, Treatment outcome, Eczema, Socio-culturale, Dermatitis, Dupilumab, atopic dermatitis, multicentre, real-life study, Dermatology, Antibodies, Monoclonal, Humanized, elderly, Severity of Illness Index, Antibodies, Atopic, Dermatitis, Atopic, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, Settore MED/35, 0302 clinical medicine, Internal medicine, Aged, Humans, Middle Aged, Retrospective Studies, Monoclonal, Medicine, 030212 general & internal medicine, Adverse effect, Humanized, atopic dermatitis, business.industry, dupilumab, Atopic dermatitis, medicine.disease, humanities, Safety profile, Infectious Diseases, Observational study, real-life study, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Life study, business, Prurigo nodularis
Abstract

Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

Published
2020

21. Hidradenitis suppurativa epidemiology. From the first Italian registry in 2009 to the most recent epidemiology updates - Italian Registry Hidradenitis Suppurativa project 2

Author

Bettoli, V., Cazzaniga, S., Scuderi, V., Zedde, P., Di Landro, A., Naldi, L., Cannavò, S., Fabbrocini, G., Marzano, A. V., Mazzanti, C., Offidani, A., Patrizi, A., Pellacani, G., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Bettoli, V., Cazzaniga, S., Scuderi, V., Zedde, P., Di Landro, A., Naldi, L., Cannavo, S., Fabbrocini, G., Marzano, A. V., Mazzanti, C., Offidani, A., Patrizi, A., Pellacani, G., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Bettoli V., Cazzaniga S., Scuderi V., Zedde P., Di Landro A., Naldi L., Cannavo S., Fabbrocini G., Marzano A.V., Mazzanti C., Offidani A., Patrizi A., Pellacani G., Pimpinelli N., Potenza C., Romanelli M., and Rongioletti F.

Subjects
Adult, Male, Registrie, medicine.medical_specialty, MEDLINE, Dermatology, Body Mass Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Age Distribution, Epidemiology, medicine, Prevalence, Humans, Hidradenitis suppurativa, Registries, Young adult, Age of Onset, Sex Distribution, business.industry, Incidence (epidemiology), Incidence, Smoking, hidradenitis suppurativa, medicine.disease, Infectious Diseases, Italy, 030220 oncology & carcinogenesis, Age distribution, Female, Age of onset, business, Body mass index, Demography, Human
Abstract

BACKGROUND The incidence of hidradenitis suppurativa (HS) is still not fully established with only a few studies reporting its estimates. Prevalence estimates range from 5:10 000 to 4:100. These extremely large variations could be explained by a combination of factors, including different selection procedures, different diagnostic criteria, and variations in the sex and age distribution of the examined samples. OBJECTIVES To analyze variations between two consecutive Italian Registries on HS. METHODS Data obtained from the second Italian Registry on HS, named 'Italian Registry Hidradenitis Suppurativa (IRHIS) Project 2', are compared to the previous first Italian registry on HS. RESULTS Data on 944 patients are reported. The more relevant aspects that characterize IRHIS 2 project, in comparison with the previous first Italian Registry on HS, are as follows: (i) the total number of patients, about fourfold higher; (ii) a more uniform national geographic distribution of the patient population; (iii) a larger number of dermatology units involved; (iv) a larger number of items considered in the data collection; (v) 6 years of difference between the onset of the two registries (2009-2013 vs. 2015-2019). Comparing data of the two registries, there are no statistically significant differences in terms of age at the time of the visit, gender, BMI, smoking habits, age at onset and age at first diagnosis by physician. Interestingly, the mean Sartorius score in the IRHIS project 2 (58.8) was significantly lower compared to the first Italian Registry (78.4). CONCLUSIONS The importance of the registries, at both national and international levels, in collecting useful real-life data is confirmed by these two Italian projects.

Published
2019

22. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience

Author

Lacarrubba, F., Dini, V., Napolitano, M., Venturini, M., Caposiena Caro, D. R., Molinelli, E., Passoni, E., Monfrecola, G., Argenziano, G., Berti, E., Bianchi, L., Calzavara Pinton, P., Cannavo, S. P., Costanzo, A., Donini, M., Fabbrocini, G., Fierro, M. T., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Peris, K., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Solivetti, F., Lacarrubba, F., Dini, V., Napolitano, M., Venturini, M., Caposiena Caro, D. R., Molinelli, E., Passoni, E., Monfrecola, G., Argenziano, G., Berti, E., Bianchi, L., Calzavara Pinton, P., Cannavo, S. P., Costanzo, A., Donini, M., Fabbrocini, G., Fierro, M. T., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Peris, K., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Solivetti, F., Lacarrubba F., Dini V., Napolitano M., Venturini M., Caposiena Caro D.R., Molinelli E., Passoni E., Monfrecola G., Argenziano G., Berti E., Bianchi L., Calzavara Pinton P., Cannavo S.P., Costanzo A., Donini M., Fabbrocini G., Fierro M.T., Micali G., Offidani A., Parodi A., Patrizi A., Pellacani G., Peris K., Pimpinelli N., Potenza C., Romanelli M., Rongioletti F., and Solivetti F.

Subjects
Adult, Male, medicine.medical_specialty, Standard of care, Dermatology, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Disease severity, Retrospective Studie, Internal medicine, medicine, Humans, Hidradenitis suppurativa, Radiation treatment planning, Grading (tumors), Physical Examination, Retrospective Studies, Ultrasonography, Settore MED/35 - Malattie Cutanee e Veneree, business.industry, Ultrasound, Retrospective cohort study, Middle Aged, medicine.disease, Hidradenitis Suppurativa, Infectious Diseases, Ultrasound Working Group experience, 030220 oncology & carcinogenesis, Female, business, Human
Abstract

Background: Ultrasound (US) is a real-time non-invasive technique that has been demonstrated to support an early diagnosis and a more precise assessment of hidradenitis suppurativa (HS). Objectives: To compare the clinical and US evaluation of a series of HS patients. Methods: 434 HS patients (259 F, 175 M; mean age 33.82 ±13.31 years) observed across 19 Italian dermatology centres [members of the Italian Ultrasound Working Group (IUWG)] were enrolled in a retrospective study. Clinical staging was obtained by the Hidradenitis Suppurativa Physician's Global Assessment score (HS-PGA), while the ultrasonographic staging was determined by the US HS-PGA, based on the same scores as clinical HS-PGA but performed with the aid of US. Results: At the end of the study, the mean clinical and US HS-PGA scores were 2.70 and 2.92, respectively. Direct comparison of clinical and ultrasonographic assessment revealed that a higher proportion of patients was classified as having moderate and very severe disease by US. In particular, 117 patients (26.96%) had a worse classification by US HS-PGA compared to clinical assessment. Conclusion: Our findings confirm that the use of clinical grading only to assess HS severity may underestimate the real disease severity. US examination can be considered an essential non-invasive imaging tool available to dermatologists for a more accurate diagnosis, staging, treatment planning and monitoring of HS and should be included in the pathway to an optimal standard of care of HS.

Published
2019

25. Effectiveness of secukinumab in the treatment of moderate–severe hidradenitis suppurativa. Results from an italian multicentric retrospective study in a real-life setting

Author

Ribero, S., Ramondetta, A., Fabbrocini, G., Bettoli, V., Potenza, C., Chiricozzi, A., Licciardello, M., Marzano, A. V., Bianchi, L., Rozzo, G., Fania, L., Marasca, C., Odorici, G., Mambrin, A., Moltrasio, C., Caposiena Caro, R. D., Skroza, N., Quaglino, P., Siliquini, N., and Dapavo, P.

Subjects
antibodies, monoclonal, humanized, humans, italy, retrospective studies, hidradenitis suppurativa
Published
2021

27. Effect of secukinumab on perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study

Author

Talamonti, M, Malara, G, Natalini, Y, Bardazzi, F, Conti, A, Chiricozzi, A, Mugheddu, C, Gisondi, P, Piaserico, S, Pagnanelli, G, Amerio, P, Potenza, C, Cantoresi, F, M Concetta Fargnoli, Balato, A, Loconsole, F, Offidani, A, Bonifati, C, Prignano, F, Bartezaghi, M, Rausa, A, Aloisi, E, Orsenigo, R, and Costanzo, A

Subjects
depression, psoriasis, quality of life, secukinumab, anxiety, Settore MED/35
Published
2021

28. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

Author

Galluzzo, M., Caldarola, Giacomo, De Simone, Clara, Bernardini, N., Moretta, G., Pallotta, S., Botti, E., Campione, E., Pirro, Federico, Potenza, C., Bianchi, L., Peris, Ketty, Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Pirro F., Peris K. (ORCID:0000-0002-5237-0463), Galluzzo, M., Caldarola, Giacomo, De Simone, Clara, Bernardini, N., Moretta, G., Pallotta, S., Botti, E., Campione, E., Pirro, Federico, Potenza, C., Bianchi, L., Peris, Ketty, Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Pirro F., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks. Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.

Published
2021

29. The clinical spectrum of COVID-19–associated cutaneous manifestations: An Italian multicenter study of 200 adult patients

Author

Marzano, A. V., Genovese, Giannicola, Moltrasio, C., Gaspari, V., Vezzoli, P., Maione, V., Misciali, C., Sena, P., Patrizi, A., Offidani, A., Quaglino, P., Arco, R., Caproni, M., Rovesti, M., Bordin, G., Recalcati, S., Potenza, C., Guarneri, C., Fabbrocini, G., Tomasini, C., Sorci, M., Lombardo, M., Gisondi, P., Conti, A., Casazza, G., Peris, Ketty, Calzavara-Pinton, P., Berti, Emanuele, Genovese G., Peris K. (ORCID:0000-0002-5237-0463), Berti E., Marzano, A. V., Genovese, Giannicola, Moltrasio, C., Gaspari, V., Vezzoli, P., Maione, V., Misciali, C., Sena, P., Patrizi, A., Offidani, A., Quaglino, P., Arco, R., Caproni, M., Rovesti, M., Bordin, G., Recalcati, S., Potenza, C., Guarneri, C., Fabbrocini, G., Tomasini, C., Sorci, M., Lombardo, M., Gisondi, P., Conti, A., Casazza, G., Peris, Ketty, Calzavara-Pinton, P., Berti, Emanuele, Genovese G., Peris K. (ORCID:0000-0002-5237-0463), and Berti E.

Abstract

Background: COVID-19 is associated with a wide range of skin manifestations. Objective: To describe the clinical characteristics of COVID-19–associated skin manifestations and explore the relationships among the 6 main cutaneous phenotypes and systemic findings. Methods: Twenty-one Italian Dermatology Units were asked to collect the demographic, clinical, and histopathologic data of 200 patients with COVID-19–associated skin manifestations. The severity of COVID-19 was classified as asymptomatic, mild, moderate, or severe. Results: A chilblain-like acral pattern was significantly associated with a younger age (P <.0001) and, after adjusting for age, significantly associated with less severe COVID-19 (P =.0009). However, the median duration of chilblain-like lesions was significantly longer than that of the other cutaneous manifestations taken together (P <.0001). Patients with moderate/severe COVID-19 were more represented than those with asymptomatic/mild COVID-19 among the patients with cutaneous manifestations other than chilblain-like lesions, but only the confluent erythematous/maculo-papular/morbilliform phenotype was significantly associated with more severe COVID-19 (P =.015), and this significance disappeared after adjustment for age. Limitations: Laboratory confirmation of COVID-19 was not possible in all cases. Conclusions: After adjustment for age, there was no clear-cut spectrum of COVID-19 severity in patients with COVID-19–related skin manifestations, although chilblain-like acral lesions were more frequent in younger patients with asymptomatic/pauci-symptomatic COVID-19.

Published
2021

30. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Author

Costanzo, A., Russo, F., Galluzzo, M., Stingeni, L., Scuderi, R., Zichichi, L., Papini, M., Di Costanzo, L., Conti, A., Burlando, M., Chiricozzi, Andrea, Gaiani, F. M., Mugheddu, C., Musumeci, M. L., Gisondi, P., Piaserico, S., Dapavo, P., Venturini, M., Pagnanelli, G., Amerio, P., Potenza, C., Peris, Ketty, Cantoresi, F., Trevisini, S., Loconsole, F., Offidani, A., Mercuri, S. R., Lora, V., Prignano, F., Bartezaghi, M., Oliva, G., Aloisi, E., Orsenigo, R., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Costanzo, A., Russo, F., Galluzzo, M., Stingeni, L., Scuderi, R., Zichichi, L., Papini, M., Di Costanzo, L., Conti, A., Burlando, M., Chiricozzi, Andrea, Gaiani, F. M., Mugheddu, C., Musumeci, M. L., Gisondi, P., Piaserico, S., Dapavo, P., Venturini, M., Pagnanelli, G., Amerio, P., Potenza, C., Peris, Ketty, Cantoresi, F., Trevisini, S., Loconsole, F., Offidani, A., Mercuri, S. R., Lora, V., Prignano, F., Bartezaghi, M., Oliva, G., Aloisi, E., Orsenigo, R., Chiricozzi A. (ORCID:0000-0002-6739-0387), and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

Published
2021

31. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

Author

Talamonti, M., Malara, G., Natalini, Y., Bardazzi, F., Conti, A., Chiricozzi, Andrea, Mugheddu, C., Gisondi, P., Piaserico, S., Pagnanelli, G., Amerio, P., Potenza, C., Cantoresi, F., Fargnoli, M. C., Balato, A., Loconsole, F., Offidani, A., Bonifati, C., Prignano, F., Bartezaghi, M., Rausa, A., Aloisi, E., Orsenigo, R., Costanzo, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Talamonti, M., Malara, G., Natalini, Y., Bardazzi, F., Conti, A., Chiricozzi, Andrea, Mugheddu, C., Gisondi, P., Piaserico, S., Pagnanelli, G., Amerio, P., Potenza, C., Cantoresi, F., Fargnoli, M. C., Balato, A., Loconsole, F., Offidani, A., Bonifati, C., Prignano, F., Bartezaghi, M., Rausa, A., Aloisi, E., Orsenigo, R., Costanzo, A., and Chiricozzi A. (ORCID:0000-0002-6739-0387)

Abstract

This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period of up to 72 weeks. Assessments used were: Psoriasis Area Sever-ity Index (PASI), Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A), and HADS - Depression (HADS-D) scores and Dermatology Quality Life Index (DLQI). Compared with baseline, a significantly greater proportion of patients who reported moderate to severe clinical symptoms of anxiety or depression (HADS-A or HADS-D ≥ 11) were free of moderate to severe symptoms at weeks 16 and 48. The PASI and DLQI scores reduced over time with secukinumab treatment. Psoriasis treatment with secukinumab for 48 weeks resulted in significantly improved skin clearance and a parallel improvement in symptoms of anxiety and depression, assessed by HADS.

Published
2021

32. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Author

Chiricozzi, Andrea, Costanzo, A., Fargnoli, M. C., Malagoli, P., Piaserico, S., Amerio, P., Argenziano, G., Balato, N., Bardazzi, F., Bianchi, L., Carrera, C. G., Conti, A., Dapavo, P., De Simone, Clara, Loconsole, F., Lo Schiavo, A., Malara, G., Musumeci, M. L., Parodi, A., Peris, Ketty, Prignano, F., Rongioletti, F., Talamonti, M., Potenza, C., Chiricozzi A. (ORCID:0000-0002-6739-0387), De Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Costanzo, A., Fargnoli, M. C., Malagoli, P., Piaserico, S., Amerio, P., Argenziano, G., Balato, N., Bardazzi, F., Bianchi, L., Carrera, C. G., Conti, A., Dapavo, P., De Simone, Clara, Loconsole, F., Lo Schiavo, A., Malara, G., Musumeci, M. L., Parodi, A., Peris, Ketty, Prignano, F., Rongioletti, F., Talamonti, M., Potenza, C., Chiricozzi A. (ORCID:0000-0002-6739-0387), De Simone C. (ORCID:0000-0002-0898-0045), and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Guselkumab, a subcutaneously administered fully human IgG1lambda monoclonal antibody that selectively inhibits the p19 subunit of interleukin 23, is approved in both the USA and the EU for the treatment of adult patients with moderate-to-severe plaque psoriasis. The efficacy and safety of guselkumab were demonstrated in four randomized, double-blind, Phase III trials (VOYAGE 1 and 2, NAVIGATE, and ECLIPSE), which demonstrated high levels of clinical response over three years of continuous treatment, regardless of sex, age, body weight, and race, maintaining a favourable safety profile and long-term tolerability. Guselkumab was shown to be efficacious in patients with prior failure of other biologics, including adalimumab and ustekinumab, and was superior to both adalimumab and secukinumab in head-to-head trials. Guselkumab efficacy was also observed in the treatment of psoriasis localized in difficult-to-treat body regions including the scalp, palms and/or soles, and fingernails. Treatment with guselkumab improved health-related quality of life and patient-reported signs and symptoms. Guselkumab has a consistently favourable safety profile and is well tolerated over the long-term. Clinical development of guselkumab as a treatment is ongoing for other immune-mediated inflammatory diseases, including psoriatic arthritis, Crohn's disease, and ulcerative colitis. In the overall management of patients with plaque psoriasis, guselkumab is a robust treatment option with durable maintenance of response over time.

Published
2021

33. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., Gallo R., Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., and Gallo R.

Abstract

Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.

Published
2021

34. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa; results of a prospective European cohort study.

Author

van Straalen, K R, Tzellos, Thrasivoulos, Guillem, P, Benhadou, Farida, Cuenca-Barrales, C, Daxhelet, Mathilde, Daoud, M, Efthymiou, O, Giamarellos-Bourboulis, E J, Jemec, Gregor B E, Katoulis, A C, Koenig, A, Lazaridou, E, Marzano, A V, Matusiak, Łukasz L., Molina-Leyva, A, Moltrasio, C, Pinter, A, Potenza, C, Romaní, J, Saunte, Ditte Marie Lindhardt D.M., Skroza, N, Stergianou, D, Szepietowski, Jacek J.C., Trigoni, A, Vilarrasa, E, van der Zee, H H, van Straalen, K R, Tzellos, Thrasivoulos, Guillem, P, Benhadou, Farida, Cuenca-Barrales, C, Daxhelet, Mathilde, Daoud, M, Efthymiou, O, Giamarellos-Bourboulis, E J, Jemec, Gregor B E, Katoulis, A C, Koenig, A, Lazaridou, E, Marzano, A V, Matusiak, Łukasz L., Molina-Leyva, A, Moltrasio, C, Pinter, A, Potenza, C, Romaní, J, Saunte, Ditte Marie Lindhardt D.M., Skroza, N, Stergianou, D, Szepietowski, Jacek J.C., Trigoni, A, Vilarrasa, E, and van der Zee, H H

Abstract

Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current Hidradenitis Suppurativa (HS) guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2021

35. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. results from extension phase of the SUPREME study

Author

Papini, M, Cusano, F, Romanelli, M, Burlando, M, Stinco, G, Girolomoni, G, Peris, K, Potenza, C, Offidani, A, Bartezaghi, M, Aloisi, E, Costanzo A, Bianchi L, Bottoni U, Buligan C, Brazzelli V, Campanati A, Cantoresi F, Capo A, Cattaneo A, Dapavo P, Del Giglio M, Di Lernia V, Di Nuzzo S, De Simone C, Dusi D, Fargnoli MC, Flori ML, Franchi C, Galluzzo M, Ghilardi A, Hansel K, Loconsole F, Lora V, Malagoli P, Malara G, Mastrandrea V, Megna M, Mercuri SR, Musumeci ML, Naldi L, Narcisi A, Orsini D, Pagnanelli G, Patrizi A, Pau M, Pellacani G, Persechino S, Piaserico S, Pietroleonardo L, Prignano F, Reseghetti A, Russo F, Sirna R, Skroza N, Stingeni L, Trevisini S, Zane C, Zichichi L, Zini A., Papini, M, Cusano, F, Romanelli, M, Burlando, M, Stinco, G, Girolomoni, G, Peris, K, Potenza, C, Offidani, A, Bartezaghi, M, Aloisi, E, Costanzo, A, Bianchi, L, Bottoni, U, Buligan, C, Brazzelli, V, Campanati, A, Cantoresi, F, Capo, A, Cattaneo, A, Dapavo, P, Del Giglio, M, Di Lernia, V, Di Nuzzo, S, De Simone, C, Dusi, D, Fargnoli, Mc, Flori, Ml, Franchi, C, Galluzzo, M, Ghilardi, A, Hansel, K, Loconsole, F, Lora, V, Malagoli, P, Malara, G, Mastrandrea, V, Megna, M, Mercuri, Sr, Musumeci, Ml, Naldi, L, Narcisi, A, Orsini, D, Pagnanelli, G, Patrizi, A, Pau, M, Pellacani, G, Persechino, S, Piaserico, S, Pietroleonardo, L, Prignano, F, Reseghetti, A, Russo, F, Sirna, R, Skroza, N, Stingeni, L, Trevisini, S, Zane, C, Zichichi, L, and Zini, A.

Subjects
Moderate to severe, medicine.medical_specialty, business.industry, secukinumab, HLA-Cw6, Dermatology, Plaque type psoriasis, moderate-to-severe plaque-type psoriasis, Clinical trial, Severity of illness, Monoclonal, Medicine, In patient, Secukinumab, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Prospective cohort study
Abstract

Recent studies have shown that biological drugs approved for treating psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the genome have been associated with different clinical responses or side effects. HLA-Cw6 gene is associated with more severe and early-onset psoriasis. Recent reports have shown that HLA-Cw6 status predicts efficacy of some biologic treatments in psoriasis patients. The Phase 3b SUPREME study (NCT02394561) demonstrated the efficacy of secukinumab in patients with moderate-to-severe plaque-type psoriasis, irrespective of HLA-Cw6 status at week 24. This article is protected by copyright. All rights reserved.

Published
2019

36. Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting

Author

Ribero, S., primary, Ramondetta, A., additional, Fabbrocini, G., additional, Bettoli, V., additional, Potenza, C., additional, Chiricozzi, A., additional, Licciardello, M., additional, Marzano, A.V., additional, Bianchi, L., additional, Rozzo, G., additional, Fania, L., additional, Marasca, C., additional, Odorici, G., additional, Mambrin, A., additional, Moltrasio, C., additional, Caposiena Caro, R.D., additional, Skroza, N., additional, Quaglino, P., additional, Siliquini, N., additional, and Dapavo, P., additional

Published
2021
Full Text
View/download PDF

37. Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study

Author

Bernardini, N, Skroza, N, Tolino, E, Marchesiello, A, Mambrin, A, Balduzzi, V, Michelini, S, Maddalena, P, Volpe, S, Proietti, I, and Potenza, C.

Subjects
Adult, Male, Biological Products, Middle Aged, Severity of Illness Index, Ointments, HIV, psoriasis, psoriasis treatment, Chronic Disease, Quality of Life, Humans, Psoriasis, Female, Prospective Studies, Skin
Abstract

Psoriasis is a multifactorial chronic inflammatory skin disease characterized by erythemato-squamous lesions with a chronic relapsing course. The desease clinical activity (PASI) and the patient's quality of life (DLQI) are the main elements to assess for setting up a correct therapeutic management.The aim of the study was to evaluate the management of the patient with moderate-severe psoriasis in therapy with biological drugs and to establish the difference in the achievement of PASI 90 and DLQI 0-1 between a group of patients treated with only biological drugs and a group of patients receiving biologic therapy in combination with a topical ointment.We conducted a prospective, observational real-life study enrolling 60 patients with moderate to severe psoriasis and divided in two groups: Group A patients treated with biological drugs, Group B patiens treated with biological drugs in association with an ointment composed of betamethasone, salicylic acid and ammonium sulpho-ichtyolate, applied 2 times a day. PASI and DLQI were evaluated at study beginning (T0) for both study groups, after 12 weeks (T3) for sample in therapy with biological drugs and after 24 weeks (T6) for sample in co-medication therapy.The two-way ANOVA method was used to evaluate the standard deviations (SD): at T3 and T6 Group B obtained a significant PASI reduction and improvement of DLQI (* p value0.05) compared to Group A.Our study shown that the patients treated with biologics in co-medication with topical therapy reached a significantly higher PASI and DQLI compared with those treated with only biologics. Furthermore we observed that the association with topical oinment showed more efficacy in the treatment of areas such as palm-plantar region, that is often difficult-to-treat region, even for biologic drugs.

Published
2020

38. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author

Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), and De Simone C. (ORCID:0000-0002-0898-0045)

Abstract

N/A

Published
2020

39. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Author

Patruno, C., Napolitano, M., Argenziano, G., Peris, Ketty, Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, Maria Teresa, Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, Maria Concetta, Ferrillo, M., Galluzzo, M., Gori, Niccolo', Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, Katia Elisabetta, Ravaioli, G. M., Ribero, S., Romanelli, Margherita, Romita, P., Tolino, E., Trifiro, C., Peris K. (ORCID:0000-0002-5237-0463), Iannone M., Fargnoli M. C., Gori N., Provenzano E., Romanelli M., Patruno, C., Napolitano, M., Argenziano, G., Peris, Ketty, Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, Maria Teresa, Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, Maria Concetta, Ferrillo, M., Galluzzo, M., Gori, Niccolo', Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, Katia Elisabetta, Ravaioli, G. M., Ribero, S., Romanelli, Margherita, Romita, P., Tolino, E., Trifiro, C., Peris K. (ORCID:0000-0002-5237-0463), Iannone M., Fargnoli M. C., Gori N., Provenzano E., and Romanelli M.

Abstract

Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe tre

Published
2020

40. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature

Author

Caldarola, Giacomo, Pirro, Federico, Di Stefani, Alessandro, Talamonti, M., Galluzzo, M., D'Adamio, S., Magnano, M., Bernardini, N., Malagoli, P., Bardazzi, F., Potenza, C., Bianchi, L., Peris, Ketty, De Simone, Clara, Caldarola G. (ORCID:0000-0002-8837-9232), Pirro F., Di Stefani A., Peris K. (ORCID:0000-0002-5237-0463), De Simone C. (ORCID:0000-0002-0898-0045), Caldarola, Giacomo, Pirro, Federico, Di Stefani, Alessandro, Talamonti, M., Galluzzo, M., D'Adamio, S., Magnano, M., Bernardini, N., Malagoli, P., Bardazzi, F., Potenza, C., Bianchi, L., Peris, Ketty, De Simone, Clara, Caldarola G. (ORCID:0000-0002-8837-9232), Pirro F., Di Stefani A., Peris K. (ORCID:0000-0002-5237-0463), and De Simone C. (ORCID:0000-0002-0898-0045)

Abstract

Background: Real-life data often highlight the side effects of certain drugs not previously reported in randomized controlled trials (RCTs). Objective: To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab). Methods: Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL-17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed. Results: Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 (5.8%) patients were collected. The eruptions appeared after a mean of 16.9 ± 17.0 weeks of therapy showing a classical acute eczema in 11 patients (40.7%), an atopic dermatitis-like rash in 11 patients (40.7%) and a psoriasiform eruption in 5 patients (18.5%). Histopathology of 12/27 cases showed epidermal spongiosis in all these variants. Conclusion: We described the clinic-pathologic features of some eczematous eruptions occurring in psoriatic patients, 3–4 months after treatment initiation with an anti IL-17A agent. Further investigations are needed to explain this phenomenon, that might be defined a paradoxical adverse event, based upon the role of IL17 in eczema pathogenesis.

Published
2020

41. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., Gallo R., Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., and Gallo R.

Abstract

na

Published
2020

42. Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore

Author

Marzano, A V, Chiricozzi, Andrea, Giovanardi, Giulia, Argenziano, G, Bettoli, V, Bianchi, L, Dapavo, P, Dini, V, Fabbrocini, G, Micali, G, Offidani, A M, Potenza, C, Prignano, F, Gualberti, G, Saragaglia, V, Rongioletti, F, Chiricozzi, A (ORCID:0000-0002-6739-0387), Giovanardi, G, Marzano, A V, Chiricozzi, Andrea, Giovanardi, Giulia, Argenziano, G, Bettoli, V, Bianchi, L, Dapavo, P, Dini, V, Fabbrocini, G, Micali, G, Offidani, A M, Potenza, C, Prignano, F, Gualberti, G, Saragaglia, V, Rongioletti, F, Chiricozzi, A (ORCID:0000-0002-6739-0387), and Giovanardi, G

Abstract

Background. Hidradenitis suppurativa (HS) is a chronic, debilitating disease with a considerable effect on patient quality of life. Its clinical severity can be measured using different scoring systems; however few of them include patient-centred parameters. Objective. To create a new scoring system for HS that includes a quality-of-life instrument, the HIDRAdisk. Methods. This post-hoc analysis was carried out within the framework of a multicentre, longitudinal, epidemiologic study conducted over 9 months on quality-of-life aspects of HS. The new severity score was created using as reference a question from the Subject Satisfaction Questionnaire (SSQ) concerning the severity of HS as evaluated by the patient. Associated variables were selected using univariable and multivariable logistic regression models. The discriminant capabilities of the final model and of the final score were evaluated by the area under the receiver operating characteristic curve and the Hosmer-Lemeshow test. Results. The study population included 308 patients with HS of any severity grade. According to the results of the regression models, the variables associated with the reference SSQ measure were number of inflammatory nodules, abscesses and draining fistulas; the HIDRAdisk score; and the number of subumbilical lesions. The HIDRAscore is obtained by the sum of the scores associated with the number of these parameters. Possible scores range from 0 to 10. Conclusion. The HIDRAscore is a new scoring system for HS severity which, in addition to the clinical evaluation by the physician, includes a validated patient-reported outcome measure, the HIDRAdisk.

Published
2020

44. Relationships between root-knot nematode resistance and plant growth in upland cotton: galling index as a criterion

Author

Zhang, Jinfa, Waddell, C., Sengupta-Gopalan, C., Potenza, C., and Cantrell, R.G.

Subjects
Root-knot -- Control, Agricultural industry, Business
Abstract

The southern root-knot nematode (RKN) [Meloidogyne incognita (Kofoid and White) Chitwood] is one of the most destructive pests in the Cotton Belt of the USA. The lack of an economical evaluation method for RKN resistance has hindered the development of resistant cultivars. This investigation was conducted to develop an improved RKN evaluation technique. Twelve genotypes including seven susceptible (S) lines, one moderately resistant (MR) line, three highly resistant (R) lines derived from 'Auburn 623 RNR,' and one [F.sub.1] between DP 33B (S) and 'Auburn 634 RNR' (R) were evaluated in the greenhouse for plant growth, RKN egg reproduction, and root galling in Experiment 1. RKN egg reproduction was highly and positively correlated with galling index and both were highly and negatively correlated with plant growth characteristics including plant height, number of leaves, plant and root weight. Galling index was confirmed to be highly significantly and negatively correlated with plant height and fresh weight in Experiment 2 with 9 parents and their 36 [F.sub.1] hybrids. Galling index had highest genotypic F value and comparable coefficient of variance (CV) to the plant characteristics, while CV for egg counts was very high. Correlation between the two greenhouse tests in the 9 parental lines as measured by galling index was highly significant. Comparison between [F.sub.1] and their parents in egg reproduction and galling revealed that the RKN resistance is partially dominant. Using a common check and double inoculation in each pot, galling index is an easy, quick and reliable method for screening large numbers of cotton plants.

Published
2006

45. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

Author

Talamonti, M, primary, Malara, G, additional, Natalini, Y, additional, Bardazzi, F, additional, Conti, A, additional, Chiricozzi, A, additional, Mugheddu, C, additional, Gisondi, P, additional, Piaserico, S, additional, Pagnanelli, G, additional, Amerio, P, additional, Potenza, C, additional, Cantoresi, F, additional, Fargnoli, M, additional, Balato, A, additional, Loconsole, F, additional, Offidani, A, additional, Bonifati, C, additional, Prignano, F, additional, Bartezaghi, M, additional, Rausa, A, additional, Aloisi, E, additional, Orsenigo, R, additional, Costanzo, A, additional, and Group, f, additional

Published
2021
Full Text
View/download PDF

48. P.209 The neuropsychological characterization of aggressive behaviour in children and adolescents with CD/ODD: preliminary results from a multicentric case-control study (MATRICS_consortium)

Author

Balia, C., primary, Carucci, S., additional, Milone, A., additional, Romaniello, R., additional, Valente, E., additional, Potenza, C., additional, Placini, F., additional, Cera, F., additional, Donno, F., additional, Montesanto, A., additional, Caligaris, G. Gatta, additional, Brovedani, P., additional, Masi, G., additional, Coghill, D., additional, Glennon, J., additional, and Zuddas, A., additional

Published
2020
Full Text
View/download PDF

49. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, M. C., primary, Esposito, M., additional, Ferrucci, S., additional, Girolomoni, G., additional, Offidani, A., additional, Patrizi, A., additional, Peris, K., additional, Costanzo, A., additional, Malara, G., additional, Pellacani, G., additional, Romanelli, M., additional, Amerio, P., additional, Cristaudo, A., additional, Flori, M. L., additional, Motolese, A., additional, Betto, P., additional, Patruno, C., additional, Pigatto, P., additional, Peccianti, C., additional, Stinco, G., additional, Zalaudek, I., additional, Bianchi, L., additional, Boccaletti, V., additional, Cannavo, S. P., additional, Cusano, F., additional, Lembo, S., additional, Mozzillo, R., additional, Gallo, R., additional, Potenza, C., additional, Rongioletti, F., additional, Tiberio, R., additional, Grieco, T., additional, Micali, G., additional, Persechino, S., additional, Pettinato, M., additional, Pucci, S., additional, Stingeni, L., additional, Caruso, C., additional, and Argenziano, G., additional

Published
2020
Full Text
View/download PDF

50. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real‐world multicentre Italian study

Author

Dattola, A., primary, Balato, A., additional, Megna, M., additional, Gisondi, P., additional, Girolomoni, G., additional, De Simone, C., additional, Caldarola, G., additional, Cama, E., additional, Piaserico, S., additional, Fargnoli, M.C., additional, Fidanza, R., additional, Parodi, A., additional, Burlando, M., additional, Offidani, A., additional, Diotallevi, F., additional, Potenza, C., additional, Conti, A., additional, Chiricozzi, A., additional, Campione, E., additional, and Bianchi, L., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results